Incyte (NASDAQ:INCY – Get Free Report) announced its quarterly earnings results on Tuesday. Incyte Stock Down 1.7%INCY traded down $2.17 during trading on Wednesday, reaching $127.76. Incyte quarterly earnings reportRevenue rose 38% year over year to $1.67 billion, while adjusted EPS of $3.09 surpassed the $2.20 consensus estimate. Incyte Q2 outlook analysisJakafi sales rose 7% to $817 million, Opzelura sales surged 173% to $450 million, and the Hematology and Oncology portfolio grew 69% to $222 million. Incyte Company Profile(Get Free Report)Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation.